Details werden geladen...
Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
Ähnliche Seiten
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
https://www.statnews.com/2026/05/21/eli-lilly-retatrutide-triple-g-weight-loss-obesity-discontinuations-trial/Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
https://www.statnews.com/2026/06/01/abivax-ulcerative-colitis-obefazimod/
Three landmark studies highlight expanded benefits of kidney drug finerenone | EurekAlert!
https://www.eurekalert.org/news-releases/1130745
A silent kidney crisis is spreading far faster than experts expected | ScienceDaily
https://www.sciencedaily.com/releases/2026/05/260529030324.htm
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies - The Economic Times
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsks-chronic-hepatitis-b-drug-helps-one-in-five-achieve-functional-cure-in-key-studies/articleshow/131366419.cms